Joacim Lindoff is to step down as CEO of medical technology company Arjo after almost eight years. At the same time, the company presents preliminary figures for the fourth quarter. The share rises on the announcement, writes Affärsvärlden in an analysis on Tuesday.

The newspaper believes that Arjo is valued slightly lower than big brother Getinge and at a clear discount to other medical technology companies such as Addlife, Medcap and larger foreign industry colleagues.

"We maintain our buy recommendation on Arjo," writes Affärsvärlden.